22.05.2013 - Danish Novo A/S has strengthened its pipeline of anti-infectives against multidrug resistant bugs by acquiring Norwegian Xellia Pharmaceuticals.
The holding company of the Danish insulin producer Novo Nordisk purchased all shares of Xellia from 3i and other shareholders. As a consequence of the US$700m transaction, Xellia’s headquarters will move from Oslo to Copenhagen. The API manufacturer, which was spun-out from Alpharma Inc in 2008, is the leading supplier of the last resort antibiotic Vancomycin, the Gram-negative killing drug Colistimethate Sodium (CMS), antifungal medicines and corticosteroids.
Xellia has built a pipeline of generic anti-infective treatments, and has extensive semi-synthetic and biological manufacturing know-how, including strain development and manufacturing. Novo's investment will allow Xellia to boost its R&D and to improve its market reach.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.